UNITY Biotechnology, Inc. to Participate in the HC Wainwright Ophthalmology Virtual Conference – GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C. Wainwright Ophthalmology Virtual Conference.

H.C. Wainwright Ophthalmology Virtual ConferenceDate:Tuesday, August 17, 2021 On-Demand Presentation Available:7:00 a.m. ET

As part of the event Anirvan Ghosh, Ph.D., chief executive officer of UNITY, will participate in the panel titled, Vision Repair Beyond Traditional Anti-VEGF Therapy What Does the Future Hold? hosted by Matthew Caufield, equity research analyst at H.C. Wainwright. To register for the event, please visit the conference website here.

A live audio webcast of the corporate presentation will be available through the Investors & Media section of UNITYs website here. An archived replay will be available for 90 days following the event.

About UNITYUNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit inage-relatedophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter and LinkedIn.

Forward-Looking StatementsThis press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, our expectations regarding potential benefits, activity, effectiveness, and safety of UBX1325, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of results of our studies of UBX1325, the timing of the expected commencement, progression, and conclusion of our studies including those of UBX1325, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that theCOVID-19worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITYs understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release.For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter endedJune 30, 2021, filed with theSecurities and Exchange Commissionon August 10, 2021, as well as other documents that may be filed by UNITY from time to time with theSecurities and Exchange Commission.

More here:
UNITY Biotechnology, Inc. to Participate in the HC Wainwright Ophthalmology Virtual Conference - GlobeNewswire